Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Pollara

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The Journal of Infectious Diseases|August 30, 2014
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responsesGenevieve G Fouda, Coleen K Cunningham, Elizabeth J McFarland, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
The Journal of Clinical Investigation|November 11, 2021
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infectionJulie L Mitchell, Justin Pollara, Kenneth Dietze, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.
Science Immunology|July 16, 2021
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primatesMaria Pino, Talha Abid, Susan Pereira Ribeiro, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Journal of Infectious Diseases|August 30, 2014
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responsesGenevieve G Fouda, Coleen K Cunningham, Elizabeth J McFarland, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
The Journal of Clinical Investigation|November 11, 2021
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infectionJulie L Mitchell, Justin Pollara, Kenneth Dietze, et al.
Plos Pathogens|February 25, 2017
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trialDavid Easterhoff, M Anthony Moody, Daniela Fera, et al.
NPJ Vaccines|December 19, 2025
ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primatesShikha Shrivastava, Joshua M Carmen, Jiae Kim, et al.
Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.
Science Immunology|July 16, 2021
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primatesMaria Pino, Talha Abid, Susan Pereira Ribeiro, et al.
Pageof 10